Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate

@article{Jabbour2006FrequencyAC,
  title={Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate},
  author={Elias J Jabbour and H M Kantarjian and Daniel P. Jones and Moshe Talpaz and Nebiyu Bekele and Stephen O'brien and Xuan Zhou and Raja Luthra and Guillermo Garcia-Manero and F J Giles and Mary Beth Rios and Srdan Verstovsek and J. C. Gal{\'a}n Cort{\'e}s},
  journal={Leukemia},
  year={2006},
  volume={20},
  pages={1767-1773}
}
Mutations of the BCR-ABL kinase domain are a common mechanism of resistance to imatinib in chronic myeloid leukemia. We screened for mutations 171 patients failing imatinib therapy. Sixty-six mutations in 23 amino acids were identified in 62 (36%) patients not responding to imatinib. Phosphate-binding loop (P-loop) mutations were the most frequent (n=24; 36%). By multivariate analysis, factors associated with development of mutations were older age (P=0.026) prior interferon therapy (P=0.026… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 157 extracted citations

Chronic Myeloid Leukemia--Prognostic Value of Mutations.

Asian Pacific journal of cancer prevention : APJCP • 2015
View 15 Excerpts
Highly Influenced

References

Publications referenced by this paper.
Showing 1-10 of 30 references

Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate.

Clinical cancer research : an official journal of the American Association for Cancer Research • 2005

Similar Papers

Loading similar papers…